Adjuvant sunitinib FDA approved for renal cell carcinoma patients at high risk of recurrence following nephrectomy.

Non-Sponsored Content

By: scienterrific | Last updated: 16 November 2017 | In: US FDA Onc\Haem Approvals, Uncategorised

Article Keywords

FDA, Pfizer, sunitinib, Sutent

On 16 November 2017, the FDA approved sunitinib malate (Sutent®, Pfizer) for the adjuvant treatment of adult renal cell carcinoma patients at high risk of recurrence following nephrectomy.

Disclaimer

This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).

Non-Sponsored Content